NCT07896421Recruiting
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally. Participants will receive intravenous infusions of mirvetuximab soravtansine as monotherapy according to the local product label and treating physician's decision. The total study duration per participant may be up to 18 months of follow-up. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 21 Oct 2026
- Primary completion date
- Apr 2030
- Lead sponsor
- AbbVie
- Diseases
- Ovarian cancer
- NCT number
- NCT07896421
What you commit to
- Study type: Observational
- Planned participants: 500
- From 21 Oct 2026 to the primary completion date, Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in a concurrent interventional clinical trial from enrollment throughout the study
Other illness
- Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label
Other
- Unwillingness or inability to comply with study requirements
Who the study is looking for
- Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment
- Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medizinische Universitaet Wien /ID# 282657 Coordinator of this site? Confirm its status | Vienna | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.